Trastuzumab deruxtecan (T-Dxd) is a novel HER2-targeted antibody–drug conjugate (ADC) developed to deliver a potent topoisomerase I inhibitor drug to HER2-expressing cancer cells with potentially reduced systemic toxicity. This evidence concerns the gene ERBB2 and cancer.